Defective Drug - Vyotorin
Vytorin is a combination drug made up of the compounds simvastatin and ezetimibe that's designed to reduce levels of LDL (bad) cholesterol and cut the risk of cardiovascular problems. It works by decreasing the production of cholesterol by the liver and inhibiting the absorption of cholesterol in the intestine.
U.S. drug regulators are investigating whether the cholesterol-lowering drug Vytorin might be linked to cancer.
The U.S. Food and Drug Administration said it has informed health-care professionals that the agency was investigating a report from the so-called Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial of a possible association between the use of Vytorin and an increased risk of a variety of cancers. The FDA said it had obtained preliminary results from the SEAS trial. The trial tested whether lowering LDL-cholesterol with Vytorin would reduce the risk of cardiovascular problems in people with narrowing of the aorta, the body's largest artery. The five-year trial did not show a reduced cardiovascular risk. But, a "larger percentage of patients treated with Vytorin were diagnosed with and died from all types of cancer combined, when compared to treatment with a placebo," the statement said.
If you are a loved one have taken Vytorin and developed cancer please contact April Cowgill at April@littlepagebooth.com
- There are currently no articles.